Regenxbio Announces Presentations at the American Academy of Ophthalmology 2020 Annual Meeting

Regenxbio announced that two oral presentations will be presented at the American Academy Ophthalmology (AAO) 2020 Annual Meeting, taking place November 13-15, 2020 in a virtual format.

The first presentation will feature data from the RGX-314 phase 1/2 subretinal trial for the treatment of wet age-related macular degeneration (AMD). Details are as follows:  

Title: Update on the Subretinal RGX-314 Gene Therapy Phase 1/2a Study for the Treatment of Neovascular AMD

Presenter: Dante Pieramici, MD, Director, California Retina Research Foundation and Partner, California Retina Consultants

Date/time: Available on-demand

Session title: RET07 – Gene- and Cell-Based Therapies

The second presentation will include data from preclinical studies of suprachoroidal delivery of RGX-314. Details are as follows:

Title: Viral and Nonviral Suprachoroidal Ocular Gene Transfer

Presenter: Peter A Campochiaro, MD, Director, Retinal Cell and Molecular Laboratory, Professor of Ophthalmology, The Wilmer Eye Institute, Johns Hopkins University School of Medicine

Date/time: Friday, November 13, 2020 at 12:36pm PST

Session title: RET07V – Gene- and Cell-Based Therapies